Solid Biosciences Inc (SLDB):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Solid Biosciences Inc (SLDB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8151
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Solid Biosciences Inc (Solid Biosciences) is a life science company focused on developing therapies for duchenne muscular dystrophy (DMD). Its pipeline product candidates include SGT-001, a microdystrophin gene therapy administered through adeno-associated virus (AAV) stabilizes dystrophin glycoprotein complex and rescue muscle function; SB-001, a monoclonal antibody to reduce fibrosis and inflammation in DMD patients. Solid Biosciences has development programs across four scientific platforms which include corrective therapies, disease-modifying therapies, disease understanding and assistive devices. The company works in collaboration with University of Massachusetts Medical School, The Duchenne Research Fund, University of Washington, Alex’s Wish, and others. Solid Biosciences is headquartered in Cambridge, Massachusetts, the US.

Solid Biosciences Inc (SLDB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Solid Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Solid Biosciences Raises USD50 Million in Series C Financing 10
Solid GT Raises USD42.5 Million in Series B Financing Round 12
Partnerships 13
Synpromics Enters into Research Partnership with Solid Biosciences 13
Solid Biosciences Enters into Agreement with University of Washington 14
Solid Biosciences Enters into Agreement with Strykagen 15
Solid Biosciences Enters into Co-Development Agreement with Northwestern University 16
Debiopharm Enters into Agreement with Solid Biosciences 17
Licensing Agreements 18
Solid Biosciences Enters into Licensing Agreement with Biotech Company 18
Solid Biosciences Enters into Licensing Agreement with University of Michigan 19
Solid GT Enters into Licensing Agreement with University of Missouri 20
Equity Offering 21
Solid Biosciences Raises USD143.8 Million in IPO of Shares 21
Solid Biosciences Inc – Key Competitors 23
Solid Biosciences Inc – Key Employees 24
Solid Biosciences Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Aug 10, 2018: Solid Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update 26
May 10, 2018: Solid Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update 28
Mar 29, 2018: Solid Biosciences Reports Full Year 2017 Financial Results and Provides Corporate Update 30
Corporate Communications 32
Sep 13, 2018: Solid Biosciences welcomes Sukumar Nagendran, M.D., to its board Of directors 32
Jun 26, 2018: Solid Biosciences Names Dr. Martin Freed As Board Director 33
Jun 07, 2017: Solid Biosciences Strengthens Leadership Team to Advance Programs for Duchenne Muscular Dystrophy 34
Clinical Trials 35
May 11, 2017: New Preclinical Data Support SGT-001 As A Novel Treatment Approach For Duchenne Muscular Dystrophy 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Solid Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Solid Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Solid Biosciences Raises USD50 Million in Series C Financing 10
Solid GT Raises USD42.5 Million in Series B Financing Round 12
Synpromics Enters into Research Partnership with Solid Biosciences 13
Solid Biosciences Enters into Agreement with University of Washington 14
Solid Biosciences Enters into Agreement with Strykagen 15
Solid Biosciences Enters into Co-Development Agreement with Northwestern University 16
Debiopharm Enters into Agreement with Solid Biosciences 17
Solid Biosciences Enters into Licensing Agreement with Biotech Company 18
Solid Biosciences Enters into Licensing Agreement with University of Michigan 19
Solid GT Enters into Licensing Agreement with University of Missouri 20
Solid Biosciences Raises USD143.8 Million in IPO of Shares 21
Solid Biosciences Inc, Key Competitors 23
Solid Biosciences Inc, Key Employees 24
Solid Biosciences Inc, Subsidiaries 25

List of Figures
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Solid Biosciences Inc (SLDB):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • TIVIT Terceirizacao de Tecnologia e Servicos SA:企業の戦略的SWOT分析
    TIVIT Terceirizacao de Tecnologia e Servicos SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competito …
  • EnergyAustralia Pty Ltd:企業の戦略的SWOT分析
    EnergyAustralia Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Glencore Plc:企業の戦略・SWOT・財務情報
    Glencore Plc - Strategy, SWOT and Corporate Finance Report Summary Glencore Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • 4D Molecular Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary 4D Molecular Therapeutics Inc (4D Molecular Therapeutics) focuses on the discovery and development of targeted and proprietary AAV gene therapy vectors and therapeutic products. The company developed a discovery platform, Directed Vector Evolution, which empowers to create customized gene de …
  • China Resources Sanjiu Medical & Pharmaceutical Co Ltd (000999):企業の財務・戦略的SWOT分析
    China Resources Sanjiu Medical & Pharmaceutical Co Ltd (000999) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the …
  • Daimler AG (DAI)-エネルギー分野:企業M&A・提携分析
    Summary Daimler AG (Daimler) is an automobile company that undertakes the manufacture, distribution and sales of premium passenger cars, commercial vehicles and related spare part and accessories. The company also provides services such as financing, leasing, fleet management, insurance, financial i …
  • Helix Resources Ltd (HLX):企業の財務・戦略的SWOT分析
    Summary Helix Resources Ltd (HRL) operates as a mining and mineral exploration company. The company carries out the business of identification, acquisition, and development of mineral properties. It explores gold, copper, zinc, uranium, nickel, and iron ore properties. HRL's projects include Colleri …
  • Africa Oil Corp (AOI):企業の財務・戦略的SWOT分析
    Summary Africa Oil Corp (AOC) is an oil and gas company that discovers, develops, explores and produces oil and gas assets. The company has oil discoveries in Ekales, Agete, Amosing, Ewoi wells in the Lokichar Basin, and others. It owns and operates various blocks including block 9, block 10A, block …
  • KKR & Co Inc (KKR):企業の財務・戦略的SWOT分析
    KKR & Co Inc (KKR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Centrais Eletricas Brasileiras S.A.:企業の戦略・SWOT・財務情報
    Centrais Eletricas Brasileiras S.A. - Strategy, SWOT and Corporate Finance Report Summary Centrais Eletricas Brasileiras S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Reliance Worldwide Corporation Ltd (RWC):企業の財務・戦略的SWOT分析
    Reliance Worldwide Corporation Ltd (RWC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Protokinetix Inc (PKTX):製薬・医療:M&Aディール及び事業提携情報
    Summary ProtoKinetix Inc (ProtoKinetix) is a biotechnology company that develops solutions for cell survival and health. The company develops anti-aging glycopeptides used to protect cell lines including hela cells, neonatal fibroblasts, adult fibroblast, human neuronal stem cells, CD34+ cells and k …
  • Gymboree Group, Inc.:企業の戦略的SWOT分析
    Gymboree Group, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Factor Therapeutics Ltd (FTT)-医療機器分野:企業M&A・提携分析
    Summary Factor Therapeutics Ltd (FTL), formerly Tissue Therapies Ltd is a developer of wound care therapeutics. The company develops treatments for acute and chronic wound healing applications such as chronic skin ulcers and burns. Its lead therapeutic candidate, VF-001 is a targeted growth factor w …
  • Cognizant Technology Solutions Corporation:戦略・SWOT・企業財務分析
    Cognizant Technology Solutions Corporation - Strategy, SWOT and Corporate Finance Report Summary Cognizant Technology Solutions Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Petron Corp (PCOR):企業の財務・戦略的SWOT分析
    Petron Corp (PCOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Dermira Inc (DERM):製薬・医療:M&Aディール及び事業提携情報
    Summary Dermira Inc (Dermira) is a biopharmaceutical company that identifies, develops and commercializes therapeutic solutions for the treatment of dermatologic diseases, such as hyperhidrosis, acne vulgaris and atopic dermatitis. The company’s product includes QBREXZA (glycopyrronium) cloth, an an …
  • Tokyo Broadcasting System Holdings Inc (9401):企業の財務・戦略的SWOT分析
    Tokyo Broadcasting System Holdings Inc (9401) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • American National Insurance Co:企業の戦略・SWOT・財務情報
    American National Insurance Co - Strategy, SWOT and Corporate Finance Report Summary American National Insurance Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Integra LifeSciences Holdings Corporation:企業のM&A・事業提携・投資動向
    Integra LifeSciences Holdings Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Integra LifeSciences Holdings Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detaile …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆